The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Achillion Pharmaceuticals Inc. | COM | 00448Q201 | 8,840 | 1,279,340 | SH | DFND | 3 | 1,279,340 | 0 | 0 | |
| Agios Pharmaceuticals Inc. | COM | 00847X104 | 148,939 | 2,109,921 | SH | DFND | 3 | 2,109,921 | 0 | 0 | |
| Alder Biopharmaceuticals | COM | 014339105 | 49,473 | 1,510,150 | SH | DFND | 3 | 1,510,150 | 0 | 0 | |
| Alexion Pharmaceuticals Inc. | COM | 015351109 | 161,774 | 1,034,428 | SH | DFND | 2 | 1,034,428 | 0 | 0 | |
| Alnylam Pharmaceuticals Inc. | COM | 02043Q107 | 91,008 | 1,132,499 | SH | DFND | 3 | 1,132,499 | 0 | 0 | |
| Celgene Corp. | COM | 151020104 | 388,254 | 3,589,298 | SH | DFND | 2 | 3,589,298 | 0 | 0 | |
| Cempra Inc. | COM | 15130J109 | 52,670 | 1,891,900 | SH | DFND | 3 | 1,891,900 | 0 | 0 | |
| Clovis Oncology Inc. | COM | 189464100 | 56,849 | 618,188 | SH | DFND | 3 | 618,188 | 0 | 0 | |
| Esperion Therapeutics | COM | 29664W105 | 21,433 | 908,542 | SH | DFND | 3 | 908,542 | 0 | 0 | |
| Gilead Sciences Inc. | COM | 375558103 | 272,438 | 2,774,596 | SH | DFND | 1 | 2,774,596 | 0 | 0 | |
| Halozyme Therapeutics Inc. | COM | 40637H109 | 93,068 | 6,929,832 | SH | DFND | 3 | 6,929,832 | 0 | 0 | |
| Incyte Corp. | COM | 45337C102 | 413,782 | 3,750,406 | SH | DFND | 3 | 3,750,406 | 0 | 0 | |
| Infinity Pharmaceuticals Inc. | COM | 45665G303 | 22,821 | 2,700,737 | SH | DFND | 3 | 2,700,737 | 0 | 0 | |
| Intercept Pharmaceuticals | COM | 45845P108 | 34,950 | 210,719 | SH | DFND | 3 | 210,719 | 0 | 0 | |
| Isis Pharmaceuticals Inc. | COM | 464330109 | 268,180 | 6,634,838 | SH | DFND | 3 | 6,634,838 | 0 | 0 | |
| Juno Therapeutics, Inc. | COM | 48205A109 | 53,100 | 1,305,000 | SH | DFND | 3 | 1,305,000 | 0 | 0 | |
| Kite Pharma, Inc. | COM | 49803L109 | 41,760 | 750,000 | SH | DFND | 3 | 750,000 | 0 | 0 | |
| Medivation Inc. | COM | 58501N101 | 109,697 | 2,581,112 | SH | DFND | 3 | 2,581,112 | 0 | 0 | |
| Neurocrine Biosciences Inc. | COM | 64125C109 | 126,196 | 3,171,552 | SH | DFND | 3 | 3,171,552 | 0 | 0 | |
| Novavax Inc. | COM | 670002104 | 58,893 | 8,330,000 | SH | DFND | 3 | 8,330,000 | 0 | 0 | |
| Prothena Corp. PLC | COM | G72800108 | 14,509 | 320,000 | SH | DFND | 3 | 320,000 | 0 | 0 | |
| PTC Therapeutics Inc. | COM | 69366J200 | 34,788 | 1,302,912 | SH | DFND | 3 | 1,302,912 | 0 | 0 | |
| Puma Biotechnology Inc. | COM | 74587V107 | 39,337 | 521,991 | SH | DFND | 3 | 521,991 | 0 | 0 | |
| Radius Health Inc. | COM | 750469207 | 296,102 | 4,272,140 | SH | DFND | 4 | 4,272,140 | 0 | 0 | |
| Regeneron Pharmaceuticals Inc. | COM | 75886F107 | 95,354 | 205,000 | SH | DFND | 2 | 205,000 | 0 | 0 | |
| Tesaro Inc. | COM | 881569107 | 46,299 | 1,154,582 | SH | DFND | 3 | 1,154,582 | 0 | 0 | |
| Tetraphase Pharmaceuticals Inc. | COM | 88165N105 | 11,057 | 1,482,114 | SH | DFND | 3 | 1,482,114 | 0 | 0 | |
| Vertex Pharmaceuticals Inc. | COM | 92532F100 | 142,197 | 1,365,445 | SH | DFND | 3 | 1,365,445 | 0 | 0 | |